2013 Polyamines Gordon Research Conference and Gordon Research Seminar
2013 Polyamines Gordon Research Conference and Gordon Research Seminar
批准号:
8528010
负责人:
John L. Cleveland
金额:
$1.5万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-05-17 至 2014-04-30
关键词:
AcademiaAgingApplications GrantsAsiaAutoimmune DiseasesAwardBacteriaBasic ScienceBiological ModelsBiologyCardiovascular DiseasesCell physiologyClinical OncologyClinical TrialsCollaborationsCommunicable DiseasesCommunitiesDevelopmentDiabetes MellitusDisabled PersonsDisciplineDiseaseEnvironmentEpigenetic ProcessEuropeFosteringFundingGenetic TranscriptionGoalsHomeostasisHumanInfusion proceduresInternationalIon ChannelIschemiaLifeLocationMalignant NeoplasmsMessenger RNAMetabolic DiseasesMetabolismMicroRNAsNeurodegenerative DisordersObesityOrganismParasitic infectionPathway interactionsPharmacologic SubstancePlantsPlayPolyaminesPostdoctoral FellowPreventionProtozoaRegulationRequest for ProposalsResearchResearch PersonnelResortRoleRunningScientistSeriesStructural BiologistStudentsTherapeuticTherapeutic AgentsTranslational ResearchTranslationsTravelVertebratesWorkYeastsanalogdata exchangedrug developmentexperienceforginggraduate studenthuman diseasemeetingsmultidisciplinarynext generationnotch proteinpathogenpolycationpostersprotein degradationpublic health relevancesmall moleculesuccesssymposiumtumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The Polyamines Gordon Research Conference (GRC) has continuously run since 1975, where it provides a multidisciplinary forum that brings together top polyamine researchers as well as young and established investigators new to the field. The 2013 Polyamines GRC will be held at Waterville Valley Resort in Waterville Valley, NH, from June 16-21, 2013, and it will be focused on the regulation and role of polyamine pathways in cell physiology, development and human disease, and on the use and development of small molecules targeting polyamine metabolism as therapeutic agents in cancer, infectious disease and metabolic disorders. The GRC is unanimously regarded as the pre-eminent venue for the presentation of the very best in polyamine research. Polyamines are small, essential polycations found in all forms of life, yet their regulation varies widely among species and polyamine homeostasis is disabled in several pathological states. In particular, polyamines play unique roles in human pathogens and polyamine metabolism is markedly altered in ischemia, cardiovascular disease, obesity, diabetes and cancer, and in autoimmune and neurodegenerative disorders. Thus, the GRC brings together top-notch researchers who study polyamines in several organisms (vertebrates, yeast, plants, protozoa and bacteria) with those assessing therapeutic applications. This collage of scientific disciplines is unique amongst GRCs and creates a remarkably stimulating environment, with experts from many disciplines, including biologists, chemists, structural biologists and clinicians, and investigators from both academia and the biotech and pharmaceutical sectors. The 2013 Polyamines GRC will feature presentations from scientists at the forefront of basic and translational polyamine research, with an emphasis on the role of polyamines in tumorigenesis and metabolic and infectious diseases. The meeting will include presentations on roles of polyamines in basic cellular processes (e.g., epigenetics, transcription, translation, ion channel function), in development and disease, the normal and aberrant control of polyamine homeostasis and transport, polyamine- targeted drug development and clinical oncology and infectious disease trials. Presentations by invited speakers will be 30 minutes, followed by 10-minute discussion period. Sessions will also include short talks by students and postdoctoral fellows whose work is chosen from poster presentations. There will be two poster sessions during the meeting. To foster participation of young scientists, the 2013 GRC is held in conjunction with the 4th Polyamines Gordon Research Seminar (GRS). The GRS provides graduate students and fellows with a constructive venue that fosters the exchange of data in the absence of all but a few senior colleagues. The GRS has made the GRC a richer, more constructive experience, as it promotes the participation of young scientists during the main conference. The interactions between GRS and GRC conferees will facilitate the sharing of new research ideas, toolsets and model systems and will forge new collaborations that will to drive the field forward.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 3
-
批准号:10171101
-
项目类别:
-
资助金额:$34.5万
-
财政年份:2021
-
负责人:John L. Cleveland
-
依托单位:
Project 3
-
批准号:10438715
-
项目类别:
-
资助金额:$33.98万
-
财政年份:2021
-
负责人:John L. Cleveland
-
依托单位:
Project 3
-
批准号:10676736
-
项目类别:
-
资助金额:$33.81万
-
财政年份:2021
-
负责人:John L. Cleveland
-
依托单位:
New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma
-
批准号:10153731
-
项目类别:
-
资助金额:$55.47万
-
财政年份:2020
-
负责人:John L. Cleveland
-
依托单位:
New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma
-
批准号:10405450
-
项目类别:
-
资助金额:$54.36万
-
财政年份:2020
-
负责人:John L. Cleveland
-
依托单位:
New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma
-
批准号:10653834
-
项目类别:
-
资助金额:$54.36万
-
财政年份:2020
-
负责人:John L. Cleveland
-
依托单位:
Epigenetic Regulation of Drug Resistance to ABT-199 in B-cell Malignancies
-
批准号:9904591
-
项目类别:
-
资助金额:$18.71万
-
财政年份:2019
-
负责人:John L. Cleveland
-
依托单位:
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer
-
批准号:10524031
-
项目类别:
-
资助金额:$71.49万
-
财政年份:2018
-
负责人:John L. Cleveland
-
依托单位:
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer
-
批准号:9710619
-
项目类别:
-
资助金额:$72.95万
-
财政年份:2018
-
负责人:John L. Cleveland
-
依托单位:
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer
-
批准号:10064576
-
项目类别:
-
资助金额:$72.95万
-
财政年份:2018
-
负责人:John L. Cleveland
-
依托单位:
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer
-
批准号:10307616
-
项目类别:
-
资助金额:$71.49万
-
财政年份:2018
-
负责人:John L. Cleveland
-
依托单位:
High Throughput Screening to Discover Ulk1 Kinase Inhibitors
-
批准号:9228381
-
项目类别:
-
资助金额:$45.31万
-
财政年份:2015
-
负责人:John L. Cleveland
-
依托单位:
High Throughput Screening to Discover Ulk1 Kinase Inhibitors
-
批准号:9020250
-
项目类别:
-
资助金额:$45.31万
-
财政年份:2015
-
负责人:John L. Cleveland
-
依托单位:
High-throughput assay development for molecular probes targeting the ULK1 kinase
-
批准号:8346406
-
项目类别:
-
资助金额:$47.71万
-
财政年份:2012
-
负责人:John L. Cleveland
-
依托单位:
Targeting Slc16a/Mct Lactate Transporters in Cancer Therapeutics
-
批准号:8597537
-
项目类别:
-
资助金额:$74.76万
-
财政年份:2012
-
负责人:John L. Cleveland
-
依托单位:
Myc-directed control of mRNA turnover in lymphopoiesis and lymphomagenesis
-
批准号:8284008
-
项目类别:
-
资助金额:$41.09万
-
财政年份:2012
-
负责人:John L. Cleveland
-
依托单位:
Targeting Slc16a/Mct Lactate Transporters in Cancer Therapeutics
-
批准号:8239135
-
项目类别:
-
资助金额:$79.38万
-
财政年份:2012
-
负责人:John L. Cleveland
-
依托单位:
High-throughput assay development for molecular probes targeting the ULK1 kinase
-
批准号:8676481
-
项目类别:
-
资助金额:$13.93万
-
财政年份:2012
-
负责人:John L. Cleveland
-
依托单位:
Myc-directed control of mRNA turnover in lymphopoiesis and lymphomagenesis
-
批准号:8886095
-
项目类别:
-
资助金额:$1.34万
-
财政年份:2012
-
负责人:John L. Cleveland
-
依托单位:
Myc-directed control of mRNA turnover in lymphopoiesis and lymphomagenesis
-
批准号:8446311
-
项目类别:
-
资助金额:$38.62万
-
财政年份:2012
-
负责人:John L. Cleveland
-
依托单位:
海外基金